Literature DB >> 6268131

Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects.

D B Brunner, G Desponds, J Biollaz, I Keller, F Ferber, H Gavras, H R Brunner, J L Schelling.   

Abstract

1 MK 421 and its lysine analogue are two new inhibitors of angiotensin converting enzyme. Ten mg of both compounds were each given p.o. to 12 normotensive volunteers to determine their effect on the various components of the renin angiotensin aldosterone system. 2 Plasma converting enzyme activity decreased to very low levels within 3 to 4 h to recover only slowly over the next 72 h. Plasma angiotensin II and aldosterone also fell but returned to baseline within 24 h, whereas plasma renin activity rose reflecting the low angiotensin II levels. 3 There was a close correlation between both angiotensin II and aldosterone levels and the logarithm of plasma converting enzyme activity demonstrating that angiotensin II and aldosterone fell only when converting enzyme activity was reduced to very low levels. 4 Mean hourly urinary sodium excretion increased markedly 6 to 10 h post-drug, while blood pressure decreased slightly. Both drugs were well tolerated. 5 Thus 10 mg of MK 421 or its lysine analogue given orally are effective and long acting angiotensin converting enzyme inhibitors.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6268131      PMCID: PMC1401601          DOI: 10.1111/j.1365-2125.1981.tb01151.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man.

Authors:  H Gavras; H R Brunner; G A Turini; G R Kershaw; C P Tifft; S Cuttelod; I Gavras; R A Vukovich; D N McKinstry
Journal:  N Engl J Med       Date:  1978-05-04       Impact factor: 91.245

2.  The measurement of angiotensin-converting enzyme in subjects receiving captopril.

Authors:  J E Roulston; G A MacGregor
Journal:  N Engl J Med       Date:  1980-08-14       Impact factor: 91.245

3.  Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients.

Authors:  H R Brunner; H Gavras; B Waeber; G R Kershaw; G A Turini; R A Vukovich; D N McKinstry; I Gavras
Journal:  Ann Intern Med       Date:  1979-01       Impact factor: 25.391

4.  Estimation of angiotensin II concentration in human plasma by radioimmunoassay. Some applications to physiological and clinical states.

Authors:  G Düsterdieck; G McElwee
Journal:  Eur J Clin Invest       Date:  1971-11       Impact factor: 4.686

5.  Measurement of concentrations of angiotensin I in human blood by radioimmunoassay.

Authors:  M A Waite
Journal:  Clin Sci       Date:  1973-07       Impact factor: 6.124

6.  Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin-converting enzyme.

Authors:  R Davis; H S Ribner; E Keung; E H Sonnenblick; T H LeJemtel
Journal:  N Engl J Med       Date:  1979-07-19       Impact factor: 91.245

7.  Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril.

Authors:  B Waeber; H R Brunner; D B Brunner; A L Curtet; G A Turini; H Gavras
Journal:  Hypertension       Date:  1980 Mar-Apr       Impact factor: 10.190

8.  Improvement of chronic congestive heart-failure by oral captopril.

Authors:  G A Turini; H R Brunner; M Gribic; B Waeber; H Gavras
Journal:  Lancet       Date:  1979-06-09       Impact factor: 79.321

9.  Conversion of angiotensin I to angiotensin II.

Authors:  K K Ng; J R Vane
Journal:  Nature       Date:  1967-11-25       Impact factor: 49.962

10.  A specific orally active inhibitor of angiotensin-converting enzyme in man.

Authors:  R K Ferguson; G A Turini; H R Brunner; H Gavras; D N McKinstry
Journal:  Lancet       Date:  1977-04-09       Impact factor: 79.321

View more
  50 in total

1.  A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor of the metalloproteases ACE and NEP, in healthy volunteers.

Authors:  M Bani; A Colantoni; M Guillaume; F Macchi; G Moroni; S Persiani
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

2.  Effects of acute and chronic cilazapril treatment in spontaneously hypertensive rats.

Authors:  W Fischli; F Hefti; J P Clozel
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

3.  Endogenous angiotensin II and baroreceptor dysfunction: a comparative study of losartan and enalapril in man.

Authors:  K M Yee; A D Struthers
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

4.  BJCP 40th anniversary: moving forward, looking back.

Authors:  Annette Gilchrist; Yoon K Loke; Andrew A Somogyi; Adam F Cohen; James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

5.  [Reproducibility of acute captopril-induced renal insufficiency with enalapril].

Authors:  W Cremer
Journal:  Klin Wochenschr       Date:  1984-01-02

6.  A potent converting enzyme inhibitor CGS 13928C. Drug profile in normal volunteers.

Authors:  M D Schaller; D B Brunner; J Nussberger; G A Turini; S B Sen; D Chen; B Waeber; H R Brunner
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man.

Authors:  G P Hodsman; J R Zabludowski; C Zoccali; R Fraser; J J Morton; G D Murray; J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

8.  Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients.

Authors:  C Richer; B Giroux; P F Plouin; B Maarek; J F Giudicelli
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

9.  Angiotensin converting enzyme inhibitors.

Authors:  W Soudijn
Journal:  Pharm Weekbl Sci       Date:  1982-10-22

10.  Pharmacokinetics and pharmacodynamics of ramipril and piretanide administered alone and in combination.

Authors:  G Ruf; S Gera; H G Luus; D Trenk; N de la Rey; K Löffler; W Schulz; E Jähnchen
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.